A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy (IIM)
Latest Information Update: 20 Oct 2023
At a glance
- Drugs PF 1801 (Primary)
- Indications Dermatomyositis; Myositis; Polymyositis
- Focus Therapeutic Use
- Acronyms FROG
- Sponsors ImmunoForge
- 17 Oct 2023 According to an ImmunoForge media release, the company has dosed the first patient and is currently enrolling patients at 10 university hospitals in South Korea, including Hanyang University Hospital.
- 17 Oct 2023 According to an ImmunoForge media release, Dr. Dae-Hyun Yoo, is the principal investigator of the Phase 2 study.
- 11 Sep 2023 Status changed from not yet recruiting to recruiting.